{"id":"W4388738295","doi":"10.1097/01.hs9.0000936192.21618.f2","title":"P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Janssen Scientific Affairs; Centre Hospitalier Universitaire de Toulouse; Universitätsklinikum Hamburg-Eppendorf; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Texas MD Anderson Cancer Center; Ankara Universitesi; University of Oxford; Université de Lille; Cancer Research Institute","keywords":"Medicine; Lenalidomide; Daratumumab; Quality of life (healthcare); Internal medicine; Multiple myeloma; Population; Dexamethasone; Subgroup analysis; Randomized controlled trial; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005387943,0.000341278,0.00170988,0.0003530906,0.0001303532,0.00001552819,0.0001053983,0.0001609244,0.0001251349],"category_scores_gemma":[0.0004595403,0.0002291837,0.0002576125,0.001965638,0.0001919134,0.0001021396,0.0000234584,0.0001676046,0.000003970178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007940551,"about_ca_system_score_gemma":0.0003126087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005208494,"about_ca_topic_score_gemma":0.004487141,"domain_scores_codex":[0.996879,0.0002466097,0.0009996236,0.0005611717,0.0007294797,0.0005841571],"domain_scores_gemma":[0.996874,0.001270983,0.0005170922,0.0004852318,0.0003533105,0.0004993964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1891121,0.0009485161,0.8008282,0.0007590398,0.004805098,0.00003633566,0.0005105113,0.0001128648,0.0002861314,0.00002018409,0.0001940503,0.002387009],"study_design_scores_gemma":[0.2134288,0.003802303,0.7780473,0.0002743946,0.00115057,0.000001520208,0.0002925619,0.001638292,0.001123521,0.000007599348,0.00002958255,0.0002035848],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994999,0.0004181727,0.000317084,0.000165945,0.0000226953,0.002974953,0.0009332409,0.00009094234,0.00007798779],"genre_scores_gemma":[0.995138,0.0001385375,0.00196356,0.00003210735,0.00002026814,0.0002592642,0.00213854,0.00005410365,0.0002556066],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02431672,"threshold_uncertainty_score":0.9345838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04459092877840427,"score_gpt":0.3177322132499836,"score_spread":0.2731412844715793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}